Native Hip Survival and Long-Term Patient-Reported Outcomes Following Acetabular Fracture

Chloe E.H. Scott, MD, MsC; *Timothy O. White, MD; Stuart Goudie; John Annan, MBBS*¹; *Deborah MacDonald, BSc*¹; *John F. Keating, MD* ¹Royal Infirmary of Edinburgh, Edinburgh, Midlothian, UNITED KINGDOM

Purpose: The aim of this study was to report long-term native hip joint survival following acetabular fracture and validated patient-reported outcome measures (PROMs).

Methods: 523 consecutive patients with acetabular fractures from 1988-2010 were included. Mean age was 51 years (range, 14-100) and 356 were male (68%). Management included: open reduction and internal fixation (ORIF) in 210 displaced fractures, 4 acute total hip arthroplasties (THAs), and nonoperative management in 209 undisplaced fractures and in 49 displaced/unreconstructable fractures in the elderly. PROMs (OHS [Oxford Hip Score], iHOT [International Hip Outcome Tool], UCLA) were collected at mean 13.2 years (range, 7.9-28.8) when radiographic review and Kaplan Meier survival analyses were also performed.

Results: 61 patients (12%) underwent late THA at mean 7.5 ± 7.6 years, 174 (33%) had died, and 85 (16%) were lost. With end point THA, 10-year survival was 80.8% (95% confidence interval [CI] 74.5-87.1) after ORIF and 95.4% (92.1-98.7) following nonoperatively managed undisplaced fractures (P <0.001). With severe posttraumatic osteoarthritis or THA as the end point 10-year survival was 79.3% (72.8 to 85.8) and 95.4 (92.1 to 98.7), respectively (P <0.001). PROMs were significantly better in nonoperatively managed undisplaced fractures compared to ORIF: OHS ($40.2 \pm 12.1 \text{ vs } 34.8 \pm 13.7$, P = 0.002); iHOT ($78.0 \pm 25.0 \text{ vs}$ 66.1 ± 30.3 , P = 0.01), and improvement in UCLA score (-0.9 \pm 2.0 vs -2.2 \pm 2.5, P = 0.001). Age was the only significant predictor of outcome following ORIF. Comparing patients <45 and those \geq 45 OHS (38.4 ± 13.3 vs 28.7 ± 12.3) and iHOT scores (72.6 ± 28.8 vs 55.0 ± 29.9) were significantly better than in patients <45 years (P <0.001) as was 10-year survival: 86.2% (78.8 to 93.5) compared to 61.4 (48.4 to 74.3) (P = 0.015). Letournel classification, hip dislocation, surgical approach, sciatic nerve palsy, and associated fractures were not significant predictors of outcome or survival after ORIF. Following late THA mean OHS was 35.3 ± 13.0 . UCLA activity score fell from median 8 to 5 following ORIF (P <0.001), but 37%returned to preinjury levels. Median UCLA score was unchanged in nonoperatively managed undisplaced fractures. Normal hip function (OHS 100%; iHOT >95%) was reported in 13% after ORIF and 33% of nonoperative undisplaced fractures.

Conclusion: The need for ORIF in displaced acetabular fractures reduces native hip survival significantly compared to nonoperatively managed undisplaced fractures, especially in patients >45 years where long-term patient-reported outcomes are also poorer.

The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device he or she wishes to use in clinical practice.